Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Carretero-Iglesia L, Hall OJ, Berret J, Pais D, Estoppey C, Chimen M, Monney T, Loyau J, Dreyfus C, Macoin J, Perez C, Menon V, Gruber I, Laurendon A, Caro LN, Gudi GS, Matsuura T, van der Graaf PH, Blein S, Mbow ML, Croasdale-Wood R, Srivastava A, Dyson MR, Matthes T, Kaya Z, Edwards CM, Edwards JR, Maiga S, Pellat-Deceunynck C, Touzeau C, Moreau P, Konto C, Drake A, Zhukovsky EA, Perro M, Pihlgren M. Carretero-Iglesia L, et al. Among authors: touzeau c. Nat Cancer. 2024 Oct;5(10):1494-1514. doi: 10.1038/s43018-024-00821-1. Epub 2024 Sep 11. Nat Cancer. 2024. PMID: 39261676 Free PMC article.
ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M. Bodet L, et al. Among authors: touzeau c. Blood. 2011 Oct 6;118(14):3901-10. doi: 10.1182/blood-2010-11-317438. Epub 2011 Aug 11. Blood. 2011. PMID: 21835956 Free article.
Cereblon expression in multiple myeloma: not ready for prime time.
Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P. Lodé L, et al. Among authors: touzeau c. Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. Br J Haematol. 2013. PMID: 23862718 Free article. No abstract available.
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.
Fouquet G, Hebraud B, Garciaz S, Stoppa AM, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Touzeau C, Tessoulin B, Fermand JP, Facon T, Attal M, Loiseau HA, Moreau P, Leleu X. Fouquet G, et al. Among authors: touzeau c. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014. J Cancer. 2014. PMID: 24665349 Free PMC article.
Elotuzumab for the treatment of multiple myeloma.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Future Oncol. 2014 May;10(6):949-56. doi: 10.2217/fon.14.56. Future Oncol. 2014. PMID: 24941981 Review.
New data on subcutaneous bortezomib.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Acta Haematol. 2015;133(1):26-8. doi: 10.1159/000362639. Epub 2014 Jul 1. Acta Haematol. 2015. PMID: 24993571 No abstract available.
Multiple myeloma: from front-line to relapsed therapies.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Am Soc Clin Oncol Educ Book. 2015:e504-11. doi: 10.14694/EdBook_AM.2015.35.e504. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993216 Free article. Review.
183 results